Gene therapy targets tough lymphoma in early trial
NCT ID NCT07211048
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests a gene therapy called LCAR02 in up to 18 people with B-cell lymphoma that has relapsed or not responded to standard treatments. The therapy uses a modified gene to target and attack cancer cells. The main goals are to check safety and see if the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19-targeted gene injection (LCAR02)
- What this could lead to
- If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell lymphoma that has returned or not responded to other therapies.
- What could go wrong
- This is a very early, small study with only 18 participants, so results may not apply broadly. There are risks of serious side effects like cytokine release syndrome and nerve toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Provincial Hospital
RECRUITINGHefei, Anhui, 230001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can antibody infusions outperform antibiotics in shielding CAR-T patients from infections?
- Engineered immune cells take aim at tough childhood leukemia
- Scientists build a biobank to crack the mystery of CAR-T cell failure
- Boosting CAR t cells: could a pill make lymphoma therapy more effective?
- Military study probes Toxins' role in lymphoma
- Off-the-Shelf immune cells take on tough lymphoma